Dr. Gaia Griguolo will discuss her research and review the poster “Association of tumor-infiltrating lymphocytes (TILs) and immune signatures with PAM50 intrinsic subtyping hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of two multicentric neoadjuvant trial” which was presented at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO). This session will explore findings from two neoadjuvant trials, focusing on how the addition of immunotherapy to chemotherapy can benefit high-risk patients. Join us to review the poster and engage in a discussion on these important findings.